Syringolin A Selectively Labels the 20 S Proteasome in Murine EL4 and Wild-Type and Bortezomib-Adapted Leukaemic Cell Lines

Chemical Genomics Centre der Max-Planck-Gesellschaft, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany.
ChemBioChem (Impact Factor: 3.06). 11/2009; 10(16):2638-43. DOI: 10.1002/cbic.200900411
Source: PubMed

ABSTRACT The natural product syringolin A (SylA) is a potent proteasome inhibitor with promising anticancer activities. To further investigate its potential as a lead structure, selectivity profiling with cell lysates was performed. At therapeutic concentrations, a rhodamine-tagged SylA derivative selectively bound to the 20 S proteasome active sites without detectable off-target labelling. Additional profiling with lysates of wild-type and bortezomib-adapted leukaemic cell lines demonstrated the retention of this proteasome target and subsite selectivity as well as potency even in clinically relevant cell lines. Our studies, therefore, propose that further development of SylA might indeed result in an improved small molecule for the treatment of leukaemia.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The ubiquitin-proteasome pathway (UPP) influences essential cellular functions including cell growth, differentiation, apoptosis, signal transduction, antigen processing and inflammatory responses. The main proteolytic component of the UPP is the 26S proteasome, which is responsible for the turnover of many cellular proteins and represents an attractive target for the treatment of pathologies such as cancer, as well as inflammatory, immune and neurodegenerative diseases. Natural and synthetic proteasome inhibitors having different chemical structures and potency have been discovered. We report herein the synthesis, proteasome inhibition and modelling studies of novel C-terminal isoxazoline vinyl ester pseudopeptides. Some new compounds that contain a C-terminal extended conjugation inhibit β1 and especially β5 proteasomal catalytic subunits with IC50 values ranging from 10 to 100 µm. These results will permit further optimization based on these structural moieties to develop more active and selective molecules. Copyright © 2014 European Peptide Society and John Wiley & Sons, Ltd.
    Journal of Peptide Science 04/2014; 20(4). DOI:10.1002/psc.2612 · 1.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Profil zeigen: Neuartige aktivitätsbasierte Sonden wurden entwickelt, die selektiv Monoaminooxidasen A und B in lebenden Zellen markieren. Mit diesen Sonden konnte gezeigt werden, dass der gegen Parkinson eingesetzte MAO‐Inhibitor Deprenyl trotz seines kovalenten Wirkmechanismus eine einzigartige Proteinspezifität aufweist.
    Angewandte Chemie 07/2012; 124(28). DOI:10.1002/ange.201201955
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increasing evidence has shown that small molecule chemistry in microbes (i.e. secondary metabolism) can modulate the microbe-host response in infection and pathogenicity. The bacterial disease melioidosis is conferred by the highly virulent, antibiotic-resistant pathogen Burkholderia pseudomallei (BP). Whereas some macromolecular structures have been shown to influ- ence BP virulence (e.g. secretion systems, cellular capsule, pili), the role of the large cryptic secondary metabolome encoded within its genome has been largely unexplored for its importance to virulence. Herein we demonstrate that BP-encoded small molecule biosynthesis is indispensible for in vivo BP pathogenicity. Promoter exchange experiments were used to induce the high-level mol- ecule production from two gene clusters (MPN and SYR) found to be essential for in vivo virulence. NMR structural characteriza- tion of these metabolites identified a new class of lipopeptide biosurfactants/biofilm modulators (the malleipeptins) and syrbactin- type proteasome inhibitors, both of which represent overlooked small molecule virulence factors for BP. Disruption of Burkhold- eria virulence by inhibiting the biosynthesis of these small molecule biosynthetic pathways may prove to be an effective strategy for developing novel melioidosis-specific therapeutics.
    Journal of the American Chemical Society 06/2014; 136(26). DOI:10.1021/ja504617n · 11.44 Impact Factor

Full-text (2 Sources)

Available from
May 31, 2014